Home > Healthcare > Biotechnology > Biotechnology R&D > Cell Viability Assays Market

Cell Viability Assays Market Trends

Report ID: GMI10906
Published Date: Aug 2024
Report Format: PDF

Download Free Sample

Cell Viability Assays Market Trends

As researchers and clinicians explore the potential of stem cells for regenerative medicine, drug discovery, and disease modeling, there is a growing need for reliable and accurate cell viability assays.
These assays are essential for assessing the health, proliferation, and functionality of stem cells, which are critical for evaluating therapeutic outcomes and optimizing treatment protocols.
Additionally, the expansion of stem cell research not only fuels demand for advanced assay technologies but also drives innovation in assay development, contributing to the overall growth of the market.
Enhanced assay capabilities enable researchers to gain more precise and actionable insights, accelerating progress in stem cell applications and ultimately advancing the field of regenerative medicine.
Thus, as stem cell research advances and its applications expand, the demand for accurate and reliable cell viability assays continues to rise, further driving overall market growth.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

The cell viability assays market was valued at USD 1.7 billion and is poised to grow at 8.5% CAGR during 2024-2032, driven by advances in biotechnology and the increasing adoption of precision medicine.

The biopharmaceutical & pharmaceutical companies segment in the market will grow at 8.6% CAGR through 2024-2032, as they are heavily involved in the drug development process

North America cell viability assays market accounted for USD 696 million in 2023 and is expected to grow at 8.3% CAGR through 2032, owing to the presence of numerous prestigious research and academic institutions.

Becton, Dickinson and Company, Bio-Rad Laboratories, Inc, BioTek Instruments, Inc. (Agilent Technologies, Inc., Biotium, Inc, Canvax Biotech S.L, Creative Bioarray, Inc, and Danaher Corporation among others.